Investing.com - LAVA Therapeutics NV (NASDAQ: LVTX) reported third quarter EPS of $-0.34, $0.15 better than the analyst estimate of $-0.49. Revenue for the quarter came in at...
Investing.com - LAVA Therapeutics NV (NASDAQ: LVTX) reported second quarter EPS of $-0.48, $0.02 better than the analyst estimate of $-0.50. Revenue for the quarter came in at...
Investing.com - LAVA Therapeutics NV (NASDAQ: LVTX) reported second quarter EPS of $-0.53, $0.04 worse than the analyst estimate of $-0.49. Revenue for the quarter came in at...
Investing.com - LAVA Therapeutics NV (NASDAQ: LVTX) reported fourth quarter EPS of $-0.57, $0.03 better than the analyst estimate of $-0.60. Revenue for the quarter came in at...
Investing.com - LAVA Therapeutics NV reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. LAVA Therapeutics NV...
Telsey lowered the price target on Nike (NKE) to $125.00 from $130.00, while reiterating its Outperform rating. The analysts anticipate mixed Q1/23 results with overall solid...
Investing.com - LAVA Therapeutics NV reported on Tuesday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. LAVA Therapeutics NV...
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers,...